DexCom (NASDAQ:DXCM) EVP Sadie Stern Sells 1,466 Shares

Key Points

• Sadie Stern, the Executive Vice President of DexCom, sold 1,466 shares at an average price of $80.00, totaling $117,280, which represents a 1.37% decrease in her overall holding of shares in the company.
• DexCom's stock price traded down to $78.00 as of Monday, with the company experiencing a 15.2% year-over-year revenue increase and earnings per share of $0.48 exceeding analysts' expectations.
• Several institutions significantly increased their stakes in DexCom, with Cim Investment Management boosting its holdings by 99.7%, indicating growing confidence among institutional investors.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president owned 105,223 shares in the company, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sadie Stern also recently made the following trade(s):

• On Monday, July 28th, Sadie Stern sold 1,466 shares of DexCom stock. The shares were sold at an average price of $88.99, for a total value of $130,459.34.
• On Thursday, June 26th, Sadie Stern sold 1,466 shares of DexCom stock. The shares were sold at an average price of $85.06, for a total value of $124,697.96.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $2.51 during trading hours on Monday, reaching $78.00. The stock had a trading volume of 4,053,985 shares, compared to its average volume of 3,930,544. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm has a 50-day moving average of $81.58 and a 200-day moving average of $79.00. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a market cap of $30.59 billion, a price-to-earnings ratio of 54.17, a PEG ratio of 1.69 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period last year, the firm earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Institutional Trading of DexCom

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cim Investment Management Inc. boosted its stake in DexCom by 99.7% in the second quarter. Cim Investment Management Inc. now owns 11,163 shares of the medical device company's stock valued at $921,000 after acquiring an additional 5,573 shares during the period. B. Riley Wealth Advisors Inc. acquired a new stake in DexCom in the second quarter worth approximately $202,000. Liontrust Investment Partners LLP lifted its position in DexCom by 3.7% in the second quarter. Liontrust Investment Partners LLP now owns 103,959 shares of the medical device company's stock worth $9,075,000 after purchasing an additional 3,700 shares during the period. Castleark Management LLC acquired a new stake in shares of DexCom during the 2nd quarter valued at $27,177,000. Finally, CYBER HORNET ETFs LLC acquired a new stake in shares of DexCom during the 2nd quarter valued at $87,000. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on DXCM shares. Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Argus assumed coverage on DexCom in a research report on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. Raymond James Financial raised their price objective on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 31st. Mizuho raised their price objective on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $106.00 target price on shares of DexCom in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.